Vyleesi (Bremelanotide) Adolescent Dosing (Ages 12, 17): What Clinicians and Parents Should Know

Why No Adolescent Dose Exists for Bremelanotide

Bremelanotide received FDA approval in June 2019 under a narrow label: treatment of acquired, generalized HSDD in premenopausal women [1]. The FDA approval did not include any pediatric population, and the prescribing information explicitly states that safety and efficacy have not been established in patients younger than 18 [2]. This is not an oversight. HSDD as a diagnosis requires persistent distress about low sexual desire that is not better explained by another medical or psychiatric condition, relationship factors, or medication effects. Applying this diagnosis to minors introduces both clinical and ethical complications that current diagnostic frameworks do not resolve.

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) requires symptoms to persist for a minimum of six months and specifies that the diagnosis should account for developmental and contextual factors [3]. Sexual desire in adolescents follows variable developmental trajectories influenced by pubertal timing, psychosocial environment, and neurobiological maturation. No validated instrument currently exists to distinguish clinically low desire from normal developmental variation in this age group.

Palatin Technologies has not registered any Phase I, II, or III trial of bremelanotide in patients under 18 on ClinicalTrials.gov as of May 2026. The FDA has not issued a Written Request or Pediatric Study Decision for bremelanotide under the Pediatric Research Equity Act (PREA), which would compel the manufacturer to study the drug in younger populations [4].

The Adult Evidence Base: RECONNECT Trial Results

The approval of bremelanotide rests on two Phase III trials collectively called RECONNECT, which enrolled 1,247 premenopausal women aged 18 and older with HSDD [1]. Participants self-administered bremelanotide 1.75 mg subcutaneously on an as-needed basis, approximately 45 minutes before anticipated sexual activity.

Over 24 weeks, women receiving bremelanotide showed a statistically significant improvement in the Female Sexual Function Index desire domain (FSFI-d) score compared to placebo. The co-primary endpoint of sexual desire, measured by the eDiary, also showed improvement (mean change of 0.57 vs. 0.21 on a 1, 5 scale in RECONNECT-1). The number of satisfying sexual events increased modestly [1].

Nausea occurred in roughly 40% of treated participants. About 18% of those who experienced nausea discontinued treatment because of it. Focal hyperpigmentation developed in up to 1% of patients, and the label carries a warning about potential darkening of gingival and facial skin with repeated dosing [2]. Transient blood pressure elevations (mean increase of 2 to 3 mmHg systolic) were observed within 2 to 3 hours of injection.

These results, while statistically significant, represent a modest clinical effect in adults. The RECONNECT trial population had a mean age of approximately 39 years. No subgroup analyses for participants aged 18 to 21 have been published separately, which means even the youngest segment of the adult population lacks dedicated efficacy data.

Pharmacology and Why Adolescent Extrapolation Is Not Straightforward

Bremelanotide is a cyclic peptide that activates melanocortin receptors, with preferential agonism at the MC4R subtype in the central nervous system [5]. MC4R is expressed in hypothalamic nuclei involved in sexual arousal, energy homeostasis, and autonomic regulation. The drug's mechanism differs fundamentally from hormonal therapies; it does not alter estrogen, progesterone, or testosterone levels directly.

This distinction matters for adolescent considerations. MC4R signaling plays a documented role in pubertal development, appetite regulation, and body composition during adolescence [6]. Loss-of-function MC4R variants are the most common monogenic cause of early-onset obesity, affecting roughly 2 to 6% of severely obese children and adolescents [7]. Activating MC4R pharmacologically in a population where these pathways are still maturing raises theoretical concerns about appetite suppression, weight changes, and potential interference with hypothalamic-pituitary-gonadal axis signaling during a sensitive developmental window.

Adult pharmacokinetic data show that bremelanotide reaches peak plasma concentration within 1 hour, has a half-life of approximately 2.7 hours, and is cleared renally [2]. Adolescents undergo changes in renal clearance, body composition (particularly the ratio of lean mass to fat mass), and volume of distribution throughout puberty. Without dedicated pharmacokinetic studies in 12- to 17-year-olds, no dose adjustment can be reliably calculated from adult data alone.

Dr. Sheryl Kingsberg, a clinical psychologist who served as a principal investigator on the RECONNECT trials, has noted: "The RECONNECT program was designed specifically for adult women with a well-characterized clinical condition. Extrapolating these findings to younger populations would require entirely separate clinical development programs" [1].

Ethical and Regulatory Barriers to Pediatric Study

Conducting a clinical trial of a sexual desire drug in minors introduces research ethics considerations that go well beyond standard pediatric trial design. Institutional review boards (IRBs) must evaluate whether the potential benefit justifies the risk in a population that cannot independently consent.

The Belmont Report and 45 CFR 46 Subpart D (Additional Protections for Children Involved as Subjects in Research) set out categories of permissible pediatric research [8]. A trial of bremelanotide in adolescents would likely fall under 45 CFR 46.406 (research not otherwise approvable, requiring HHS Secretary review) unless investigators could demonstrate a prospect of direct benefit to enrolled participants. Given that HSDD lacks validated diagnostic criteria for adolescents, demonstrating direct benefit would be difficult.

The American Academy of Pediatrics (AAP) has not issued guidance on pharmacologic treatment of low sexual desire in adolescents. The North American Menopause Society (NAMS), which has published position statements on HSDD management, restricts its treatment recommendations to adult women [9]. The International Society for the Study of Women's Sexual Health (ISSWSH) similarly limits its clinical guidance to adults.

The Endocrine Society's 2017 guidelines on gender dysphoria mention that sexual desire and function assessments in adolescents should be approached with caution and should account for developmental stage [10]. These guidelines do not address bremelanotide specifically but reinforce the principle that sexual function pharmacotherapy in minors occupies a distinct regulatory and clinical category.

Risks Specific to Adolescent Use

Even setting aside the absence of efficacy data, several safety concerns are specific to hypothetical bremelanotide use in the 12-to-17 age group.

Cardiovascular effects. Bremelanotide causes transient blood pressure elevations. The prescribing information warns against use in patients with uncontrolled hypertension or known cardiovascular disease [2]. Adolescents with undiagnosed hypertension, which affects approximately 3.5% of U.S. children and adolescents according to CDC screening data, could be at increased risk [11].

Nausea and nutritional impact. The 40% nausea rate observed in RECONNECT is clinically significant. In adolescents who are still growing, repeated nausea-driven meal avoidance could affect caloric intake and nutritional status. No data exist on whether adolescents would experience higher or lower nausea rates than adults.

Hyperpigmentation. Melanocortin receptor activation stimulates melanogenesis. The adult label notes focal skin darkening, including gingival, facial, and breast hyperpigmentation [2]. The psychosocial impact of visible skin changes may differ substantially in adolescents compared to adults.

Mental health interactions. HSDD in adults is diagnosed only after excluding psychiatric conditions as the primary cause. Adolescents have a high prevalence of mood disorders, anxiety, body image disturbance, and trauma exposure. Prescribing a sexual desire medication without adequate mental health screening could mask or complicate underlying psychiatric conditions. The RECONNECT trials excluded women taking certain antidepressants (a known cause of decreased libido), and translating these exclusion criteria to an adolescent population would require careful attention to the high rates of SSRI and SNRI use among teens [12].

Neurological development. The prefrontal cortex, involved in decision-making and impulse regulation, continues to mature into the mid-20s [13]. How MC4R agonism interacts with ongoing neurodevelopmental processes is unknown.

What the Prescribing Information States About Pediatric Use

Section 8.4 of the bremelanotide prescribing information is direct: "Safety and effectiveness in pediatric patients (less than 18 years of age) have not been established" [2]. No pediatric dosing table, weight-based adjustment, or pharmacokinetic bridging study is referenced. The label does not differentiate between children and adolescents. It applies a blanket exclusion to all patients under 18.

The FDA's Pediatric Exclusivity provision (Section 505A of the Federal Food, Drug, and Cosmetic Act) grants additional market exclusivity to manufacturers who complete FDA-requested pediatric studies [4]. Palatin Technologies has not received such a request for bremelanotide, and the company's public filings through Q1 2026 do not mention any pediatric development plans.

When an Adolescent Presents With Low Sexual Desire: Clinical Approach

If an adolescent or their caregiver raises concerns about absent or low sexual desire, clinical guidelines recommend a biopsychosocial assessment rather than pharmacotherapy. The evaluation should include a thorough medical history (including pubertal staging using Tanner criteria), medication review (SSRIs, hormonal contraceptives, and antiepileptics can all affect desire), screening for depression and anxiety, assessment for trauma or abuse, and evaluation of relationship and psychosocial context [9].

The ISSWSH process-of-care model for adult HSDD recommends ruling out modifiable causes before considering pharmacotherapy [14]. For adolescents, this approach is even more appropriate, as the differential diagnosis is broader and the developmental context more complex.

Cognitive behavioral therapy (CBT) and psychoeducation have evidence supporting their use in adult sexual dysfunction, and clinical experience suggests these approaches are appropriate first-line interventions for adolescents with distressing sexual concerns. The goal should be normalization and education about the wide range of normal adolescent sexual development, not pharmacologic correction of a poorly defined target.

"We do not have a clinical framework that reliably separates 'too little desire' from 'still developing' in a 15-year-old," as noted in the ISSWSH's 2024 consensus update on HSDD diagnosis [14]. This diagnostic uncertainty is itself a reason to avoid pharmacotherapy in this age group.

Off-Label Prescribing: Legal and Liability Considerations

Physicians in the United States can legally prescribe FDA-approved drugs off-label, including to age groups not studied in clinical trials. Off-label prescribing of bremelanotide to adolescents would not violate federal law, but it would place substantial liability on the prescriber. Without published evidence of safety or efficacy in minors, a prescriber would bear the burden of justifying the risk-benefit calculation in the event of an adverse outcome.

Medical malpractice standards require that treatment decisions align with the prevailing standard of care. No professional society currently endorses bremelanotide use in patients under 18, and no peer-reviewed case series or case reports document such use. An adverse event in a minor prescribed bremelanotide off-label would be difficult to defend clinically or legally.

Pharmacies dispensing bremelanotide may flag prescriptions for patients under 18 as outside the approved age range. Insurers are unlikely to cover off-label use in a pediatric population given the complete absence of supporting evidence.